44. Cinar B, Yeung F, Konaka H, Mayo MW, Freeman MR, et al. (2004) Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kB signalling in prostate cancer cells. Biochem J 379: 421–431. 45. Zhang M, Magit D, Sager R (1997) Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci U S A 94: 5673–5678. 46. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, et al. (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47: 52–58. Androgen Regulation of 5a-Reductase Isoenzymes 47. Reid J, Murray I, Watt K, Betney R, McEwan IJ (2002) The androgen receptor interacts with multiple regions of the large subunit of general transcription factor TFIIF. J Biol Chem 277: 41247–41253. 48. Chesire DR, Isaacs WB (2002) Ligand-dependent inhibition of beta-catenin/ TCF signaling by androgen receptor. Oncogene 21: 8453–8469. 49. Yamana K, Labrie F, Luu-The V (2010) Human type 3 5areductase is expressed in peripheral tissues at higher levels than type 1 and type 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Invest 2: 293–299. PLoS ONE | www.plosone.org 12 December 2011 | Volume 6 | Issue 12 | e28840